榮暉國際(00990.HK)擬2680萬元收購山東鑫盛達67%股權
格隆匯6月15日丨榮暉國際(00990.HK)宣佈,於2021年6月15日,公司間接全資附屬公司競點(福建)國際貿易有限公司("競點(福建)")擬向賣方周飛收購山東鑫盛達礦業有限公司("山東鑫盛達")67%的全部已發行股本,代價為人民幣2680萬元。
據悉,山東鑫盛達為於中國註冊成立的有限責任公司,其主要業務為礦產品及商品(例如鐵礦石)的選礦、初加工及銷售。
公吿稱,除專注於其現有業務外,集團一直不時探索可行的投資機遇,以使其業務多元化及拓寬其收入來源,確保可持續增長,尤其是在中國,對大宗商品的需求持續高企,業務增長機會充足。收購事項為公司在中國擴展商品相關業務的良機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.